Follow Us:
Friday, May 29, 2020

UK healthcare workers begin COVID-19 hydroxychloroquine trial

The ‘COPCOV’ study will involve more than 40,000 frontline healthcare workers from Europe, Africa, Asia and South America to determine if chloroquine and hydroxychloroquine are effective in preventing the novel coronavirus.

By: Reuters | London | Published: May 21, 2020 4:23:44 pm
hydroxychloroquine coronavirus, hydroxychloroquine tablet, hydroxychloroquine uses, hydroxychloroquine Trump, hydroxychloroquine Trump coronavirus, trump coronavirus medicine,hcq tablet coronavirus, covid-19 hcq tablet, hcq tablet uses Demand for hydroxychloroquine surged after Trump touted it in early April. (File/AP)

British healthcare workers will on Thursday begin taking part in a University of Oxford-led international trial of two anti-malarial drugs to see if they can prevent COVID-19, including one US President Donald Trump says he has been taking.

The ‘COPCOV’ study will involve more than 40,000 frontline healthcare workers from Europe, Africa, Asia and South America to determine if chloroquine and hydroxychloroquine are effective in preventing the novel coronavirus.

Demand for hydroxychloroquine surged after Trump touted it in early April. Earlier this week the U.S. leader said he was now taking the drug as preventive medicine against the virus despite medical warnings about its use.

The trial, led by the University of Oxford with the support of the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok, will open to British participants at hospital sites in Brighton and Oxford on Thursday and involve those who are in close contact with patients with proven or suspected COVID-19.

Read | US commits $1.2 billion to possible British Covid-19 vaccine

“We really do not know if chloroquine or hydroxychloroquine are beneficial or harmful against COVID-19,” said the University of Oxford’s Professor Nicholas White, the study’s co-principal investigator, who is based at MORU.

“The best way to find out if they are effective in preventing COVID-19 is in a randomised clinical trial.”

The COPCOV team said laboratory evidence showed the anti-malarial drugs might be effective in preventing or treating COVID-19 but there was no conclusive proof.

US regulators have authorized the emergency use of hydroxychloroquine for coronavirus patients but the U.S. Food and Drug Administration has warned against the use of it in COVID-19 patients outside of the hospital or clinical trials due to the risk of serious heart rhythm problems.

“These trials will give us the best understanding of how safe and effective these drugs might be across different populations and age groups,” said Nick Cammack, COVID-19 Therapeutics Accelerator Lead at the Wellcome Trust, a UK-based medical research charity which is helping to fund the trial.

“If, and only if, they are effective, these drugs can be scaled up and rolled out quickly across the world.”

📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Coronavirus Outbreak News, download Indian Express App.

Advertisement
Advertisement
Advertisement
Advertisement